Dr. Xiaogang Li is a Professor of Medicine at the Mayo Clinic and an Honorary Investigator at Mayo Translational PKD Center. He is also a Professor of Biochemistry and Molecular Biology at Mayo. He obtained his Bachelor’s degree from Hangzhou University, his Master’s degree from the Chinese Academy of Sciences, and his Ph.D. from the University of Minnesota. He completed his Postdoctoral Training at Harvard Medical School. His research encompasses both basic science and translational aspects of PKD. In particular, he is widely regarded as one of the world’s foremost authorities on epigenetics and renal inflammation in PKD. Furthermore, he re-evaluates the roles of apoptosis in autosomal dominant PKD, contributing to a better understanding of the mechanisms of this disease. He has published extensively in the field including publications in Nature Cell Biology, Nature Medicine, and Journal of Clinical Investigation. His studies are leading to the use of promising new therapeutic drugs in PKD treatment. In addition, he served as the editor of a book entitled “Polycystic Kidney Disease” (2015), which was the first PKD book on the NIH bookshelf.